Cat#: EV-001-0300-A2 (5 x 10^9 EVs in 50 µl buffer)Origin/cell factory:
human adipose-derived MSCs (Cat# CHT-001-0300)Enrichment/storage medium:
tangential flow filtration, 20 mM HEPESCharacteristics:
100-200 nm, 3700 µg proteins (1 x 10^9 EVs), sterile, Endotoxin level < 0.01 EU/mlApplication:
research&development, not for clinical use
Presence of typical EV marker proteins
EVs derived from ASC/TERT300 cells carry typical surface proteins such as CD81, CD9 and CD63 as demonstrated by bead-based flow cytometry, using hCD81 positive isolation beads. Delta mean fluorescence intensity (DMFI) was calculated by normalizing to MFI of control beads.
Anti-inflammatory activity of extracellular vesicles from ASC/TERT300
Treatment of mouse macrophage cells (RAW264.7) with lipopolysaccharide (LPS) induces the formation of nitric oxide (NO) formation indicating an inflammatory reaction.
Anti-fibrotic activity of extracellular vesicles from ASC/TERT300
Treatment of human fibroblasts (fHDF/TERT166) with Transforming Growth Factor beta (TGF-ß1) induces the expression of alpha smooth muscle actin (α-SMA) indicating myofibroblast differentiation/activation, which is a key event in physiological and pathological tissue repair.
Addition of EVs derived from ASC/TERT300 cells significantly reduces α-SMA induction, indicating an anti-fibrotic activity of the EVs.
Upon arrival immediately transfer the product to -80°C.
Store product at -80°C (for up to 6 months) until use.
Thaw the EVs on ice, centrifuge before opening the tube to ensure that the solution is collected at the bottom of the tube. Then, mix carefully by pipetting up and down and aliquot for further use to avoid multiple freeze thaw cycles.
Store the aliquots at -80°C until use.
After thawing, store the EVs at 4°C for a maximum of 1 day.
Product data sheet – certificate of analysis
is available upon request | Please contact us indicating the respective LOT numbers
Data on Markers and Functions
Study of wound healing
Development of new anti-inflammatory approaches
Development of a new therapy for the treatment of COVID-19
Selected publications: exosomes for the treatment of COVID-19
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. (2020) Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020 Jun 15;29(12):747-754. https://pubmed.ncbi.nlm.nih.gov/32425691/
Verena Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolati B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, Hill AF, Hoffman AM, de Kleijn D, Levine BL, Lim R, Lötvall J, Mitsialis SA, Monguió-Tortajada M, Muraca M, Nieuwland R, Nowocin A, O’Driscoll L, Ortiz LA, Phinney DG, Reischl I, Rohde E, Sanzenbacher R, Théry C, Toh WS, Witwer KW, Lim SK, Giebel B. (2020) International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. Cytotherapy. 22(9):482-485. https://pubmed.ncbi.nlm.nih.gov/32425691/
Selected publications: extracellular vesicles for the treatment of wounds
Casado-Díaz A, Quesada-Gómez JM, Dorado G. (2020) Extracellular Vesicles Derived From Mesenchymal Stem Cells (MSC) in Regenerative Medicine: Applications in Skin Wound Healing. Front Bioeng Biotechnol. 8:146. https://pubmed.ncbi.nlm.nih.gov/32195233/